{"count": 9, "results": [{"_id": "35955427", "pmid": 35955427, "pmcid": "PMC9368983", "title": "Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders", "journal": "Int J Mol Sci", "authors": ["Li N", "Zhou T", "Fei E"], "date": "2022-07-27T00:00:00Z", "doi": "10.3390/ijms23158281", "meta_date_publication": "2022 Jul 27", "meta_volume": "23", "meta_issue": "15", "meta_pages": "", "score": 50265.82, "text_hl": "In a clinical study, chronic @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment significantly improved cognitive function in female @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ or prediabetic @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@. ", "citations": {"NLM": "Li N, Zhou T, Fei E. Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders Int J Mol Sci. 2022 Jul 27;23(15):. PMID: 35955427", "BibTeX": "@article{35955427, title={Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders}, author={Li N and Zhou T and Fei E}, journal={Int J Mol Sci}, volume={23}, number={15}}"}}, {"_id": "34440563", "pmid": 34440563, "pmcid": "PMC8401631", "title": "Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence", "journal": "Life (Basel)", "authors": ["Jones BDM", "Farooqui S", "Kloiber S", "Husain MO", "Mulsant BH", "Husain MI"], "date": "2021-08-11T00:00:00Z", "doi": "10.3390/life11080819", "meta_date_publication": "2021 Aug 11", "meta_volume": "11", "meta_issue": "8", "meta_pages": "", "score": 50255.805, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ for @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@", "citations": {"NLM": "Jones BDM, Farooqui S, Kloiber S, Husain MO, Mulsant BH, Husain MI. Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence Life (Basel). 2021 Aug 11;11(8):. PMID: 34440563", "BibTeX": "@article{34440563, title={Targeting Metabolic Dysfunction for the Treatment of Mood Disorders: Review of the Evidence}, author={Jones BDM and Farooqui S and Kloiber S and Husain MO and Mulsant BH and Husain MI}, journal={Life (Basel)}, volume={11}, number={8}}"}}, {"_id": "32500486", "pmid": 32500486, "title": "The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.", "journal": "Neurotherapeutics", "authors": ["Abdallah MS", "Mosalam EM", "Zidan AA", "Elattar KS", "Zaki SA", "Ramadan AN", "Ebeid AM"], "date": "2020-10-01T00:00:00Z", "doi": "10.1007/s13311-020-00878-7", "meta_date_publication": "2020 Oct", "meta_volume": "17", "meta_issue": "4", "meta_pages": "1897-1906", "score": 50255.49, "text_hl": "Accordingly, we proposed that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ would show antidepressant effects in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@major depressive disorder@@@ (@<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@) without other comorbidities. ", "citations": {"NLM": "Abdallah MS, Mosalam EM, Zidan AA, Elattar KS, Zaki SA, Ramadan AN, Ebeid AM. The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. Neurotherapeutics. 2020 Oct;17(4):1897-1906. PMID: 32500486", "BibTeX": "@article{32500486, title={The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.}, author={Abdallah MS and Mosalam EM and Zidan AA and Elattar KS and Zaki SA and Ramadan AN and Ebeid AM}, journal={Neurotherapeutics}, volume={17}, number={4}, pages={1897-1906}}"}}, {"_id": "39788458", "pmid": 39788458, "title": "Glucose metabolism impairment in major depressive disorder.", "journal": "Brain Res Bull", "authors": ["Meng F", "Wang J", "Wang L", "Zou W"], "date": "2025-01-07T00:00:00Z", "doi": "10.1016/j.brainresbull.2025.111191", "meta_date_publication": "2025 Jan 7", "meta_volume": "221", "meta_issue": "", "meta_pages": "111191", "score": 50254.008, "text_hl": "Herein, we summarized the impairment of @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ metabolism and its pathophysiological mechanisms in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@. In addition, we briefly discussed potential pharmacological interventions for @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ metabolism to alleviate @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@, including @GENE_GLP1R @GENE_2740 @@@glucagon-like peptide-1 receptor@@@ agonists, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, topical @GENE_INS @GENE_3630 @@@insulin@@@, liraglutide, and @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@, to encourage the development of new therapeutics.", "citations": {"NLM": "Meng F, Wang J, Wang L, Zou W. Glucose metabolism impairment in major depressive disorder. Brain Res Bull. 2025 Jan 7;221():111191. PMID: 39788458", "BibTeX": "@article{39788458, title={Glucose metabolism impairment in major depressive disorder.}, author={Meng F and Wang J and Wang L and Zou W}, journal={Brain Res Bull}, volume={221}, pages={111191}}"}}, {"_id": "36624849", "pmid": 36624849, "pmcid": "PMC9822965", "title": "How does IL-6 change after combined treatment in MDD patients? A systematic review", "journal": "Brain Behav Immun Health", "authors": ["Lombardi AL", "Manfredi L", "Conversi D"], "date": "2022-12-24T00:00:00Z", "doi": "10.1016/j.bbih.2022.100579", "meta_date_publication": "2023 Feb", "meta_volume": "27", "meta_issue": "", "meta_pages": "100579", "score": 50252.547, "text_hl": " administered to @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@ @SPECIES_9606 @@@patients@@@ @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ or placebo with @CHEMICAL_Fluoxetine @CHEMICAL_MESH:D005473 @@@fluoxetine@@@ once a day for 12 weeks. ", "citations": {"NLM": "Lombardi AL, Manfredi L, Conversi D. How does IL-6 change after combined treatment in MDD patients? A systematic review Brain Behav Immun Health. 2023 Feb;27():100579. PMID: 36624849", "BibTeX": "@article{36624849, title={How does IL-6 change after combined treatment in MDD patients? A systematic review}, author={Lombardi AL and Manfredi L and Conversi D}, journal={Brain Behav Immun Health}, volume={27}, pages={100579}}"}}, {"_id": "36071262", "pmid": 36071262, "title": "Retraction Note: The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.", "journal": "Neurotherapeutics", "authors": ["Abdallah MS", "Mosalam EM", "Zidan AA", "Elattar KS", "Zaki SA", "Ramadan AN", "Ebeid AM"], "date": "2022-09-01T00:00:00Z", "doi": "10.1007/s13311-022-01291-y", "meta_date_publication": "2022 Sep", "meta_volume": "19", "meta_issue": "5", "meta_pages": "1687", "score": 50251.645, "text_hl": "Retraction Note: The Antidiabetic @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as an Adjunct to Antidepressants in @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@Major Depressive Disorder@@@: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.", "citations": {"NLM": "Abdallah MS, Mosalam EM, Zidan AA, Elattar KS, Zaki SA, Ramadan AN, Ebeid AM. Retraction Note: The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. Neurotherapeutics. 2022 Sep;19(5):1687. PMID: 36071262", "BibTeX": "@article{36071262, title={Retraction Note: The Antidiabetic Metformin as an Adjunct to Antidepressants in Patients with Major Depressive Disorder: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.}, author={Abdallah MS and Mosalam EM and Zidan AA and Elattar KS and Zaki SA and Ramadan AN and Ebeid AM}, journal={Neurotherapeutics}, volume={19}, number={5}, pages={1687}}"}}, {"_id": "32346286", "pmid": 32346286, "pmcid": "PMC7167265", "title": "Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program", "journal": "Patient Prefer Adherence", "authors": ["AlHussain F", "AlRuthia Y", "Al-Mandeel H", "Bellahwal A", "Alharbi F", "Almogbel Y", "Awwad O", "Dala'een R", "Alharbi FA"], "date": "2020-04-15T00:00:00Z", "doi": "10.2147/PPA.S244273", "meta_date_publication": "2020", "meta_volume": "14", "meta_issue": "", "meta_pages": "737-746", "score": 50244.387, "text_hl": "The @SPECIES_9606 @@@women@@@ on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ had 70% lower odds of having @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@major depression@@@ (PHQ-9>=10) (OR=0.302, P=0.045); however, no significant effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @DISEASE_Anxiety @DISEASE_MESH:D001007 @@@anxiety@@@ (@DISEASE_general_anxiety_disorder @DISEASE_MESH:C000726808 @@@GAD-7@@@>=10) was found.", "citations": {"NLM": "AlHussain F, AlRuthia Y, Al-Mandeel H, Bellahwal A, Alharbi F, Almogbel Y, Awwad O, Dala'een R, Alharbi FA. Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program Patient Prefer Adherence. 2020;14():737-746. PMID: 32346286", "BibTeX": "@article{32346286, title={Metformin Improves the Depression Symptoms of Women with Polycystic Ovary Syndrome in a Lifestyle Modification Program}, author={AlHussain F and AlRuthia Y and Al-Mandeel H and Bellahwal A and Alharbi F and Almogbel Y and Awwad O and Dala'een R and Alharbi FA}, journal={Patient Prefer Adherence}, volume={14}, pages={737-746}}"}}, {"_id": "27978584", "pmid": 27978584, "title": "PPAR-gamma Agonists for the Treatment of Major Depression: A Review.", "journal": "Pharmacopsychiatry", "authors": ["Colle R", "de Larminat D", "Rotenberg S", "Hozer F", "Hardy P", "Verstuyft C", "Fève B", "Corruble E"], "date": "2017-03-01T00:00:00Z", "doi": "10.1055/s-0042-120120", "meta_date_publication": "2017 Mar", "meta_volume": "50", "meta_issue": "2", "meta_pages": "49-55", "score": 50055.36, "text_hl": "Methods: From 8 studies, 4 open-label trials, and 4 randomized controlled trials (RCT) (3 vs. placebo and 1 vs. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@), 448 @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@major depression@@@ were included, of which 209 @SPECIES_9606 @@@patients@@@ received PPAR-gamma agonists (@CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@ or @CHEMICAL_Rosiglitazone @CHEMICAL_MESH:D000077154 @@@rosiglitazone@@@) for 6-12 weeks, either alone or in add-on therapy to conventional treatments. ", "citations": {"NLM": "Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, Fève B, Corruble E. PPAR-gamma Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry. 2017 Mar;50(2):49-55. PMID: 27978584", "BibTeX": "@article{27978584, title={PPAR-gamma Agonists for the Treatment of Major Depression: A Review.}, author={Colle R and de Larminat D and Rotenberg S and Hozer F and Hardy P and Verstuyft C and Fève B and Corruble E}, journal={Pharmacopsychiatry}, volume={50}, number={2}, pages={49-55}}"}}, {"_id": "22999261", "pmid": 22999261, "title": "Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.", "journal": "Psychoneuroendocrinology", "authors": ["Kashani L", "Omidvar T", "Farazmand B", "Modabbernia A", "Ramzanzadeh F", "Tehraninejad ES", "Ashrafi M", "Tabrizi M", "Akhondzadeh S"], "date": "2013-06-01T00:00:00Z", "doi": "10.1016/j.psyneuen.2012.08.010", "meta_date_publication": "2013 Jun", "meta_volume": "38", "meta_issue": "6", "meta_pages": "767-76", "score": 50045.14, "text_hl": "We conducted the present study to compare the antidepressant efficacy of @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@ with another @GENE_INS @GENE_3630 @@@insulin@@@-sensitizer, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, in @DISEASE_Obesity @DISEASE_MESH:D009765 @@@obese@@@ @SPECIES_9606 @@@patients@@@ with concomitant @DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@polycystic ovarian syndrome@@@ (@DISEASE_Polycystic_Ovary_Syndrome @DISEASE_MESH:D011085 @@@PCOS@@@) and @<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@major depressive disorder@@@ (@<m>DISEASE_Depressive_Disorder_Major</m> @DISEASE_MESH:D003865 @@@MDD@@@). ", "citations": {"NLM": "Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013 Jun;38(6):767-76. PMID: 22999261", "BibTeX": "@article{22999261, title={Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.}, author={Kashani L and Omidvar T and Farazmand B and Modabbernia A and Ramzanzadeh F and Tehraninejad ES and Ashrafi M and Tabrizi M and Akhondzadeh S}, journal={Psychoneuroendocrinology}, volume={38}, number={6}, pages={767-76}}"}}]}